skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

O03/28  Cost-economics analysis of mechanical thrombectomy in patients with Low ASPECTS score through Europe

Journal of neurointerventional surgery, 2023, Vol.15 (Suppl 2), p.A1-A2 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1759-8478 ;EISSN: 1759-8486 ;DOI: 10.1136/jnis-2023-ESMINT.3

Full text available

Citations Cited by
  • Title:
    O03/28  Cost-economics analysis of mechanical thrombectomy in patients with Low ASPECTS score through Europe
  • Author: Moreu, Manuel ; Rosati, Santiago ; Pérez-García, Carlos ; Alfonso López-Frías López-Jurado ; Gómez-Escalonilla, Carlos ; Patricia Simal Hernández ; Egido Herrero, José Antonio ; Arrazola, Juan ; Barthe, Thomas ; Scarica, Raffaele ; Bocquet, Anne-Laure
  • Subjects: Cost analysis
  • Is Part Of: Journal of neurointerventional surgery, 2023, Vol.15 (Suppl 2), p.A1-A2
  • Description: IntroductionTreating with mechanical thrombectomy Low ASPECTS score (3–5) patients improve the prognosis and Rankin score. Results have been published in three recent clinical trials and furthermore are to be published regarding this specific group of patients.Further studies should determine the economic viability of expanding the indication to Low ASPECTS score patients.Aim of StudyTo demonstrate, by a cost-effectiveness analysis, the efficiency of mechanical thrombectomy (MT) versus medical management (MM) in patients with a low ASPECTS Score from the RESCUE Study.MethodsA cost-effectiveness model was designed to project both direct medical costs and quality-adjusted life-years (QALYs) of MT versus MM in eight European countries (Spain, UK, France, Italy, Belgium, Germany, Sweden, and the Netherlands). Our model was created based on previously published health-economic data in those countries. Procedure costs, acute, mid-term, and long- term care costs were projected based on expected modified Rankin Scale (mRS) scores as reported in the RESCUE- Japan LIMIT trial.ResultsMT was found to be a cost- effective option in eight different countries across Europe with a lifetime incremental cost- effectiveness ratio varying from US$2 875 to US$11 202/QALY depending on the country. A cost-effectiveness acceptability curve showed 100% acceptability of MT at the willingness to pay (WTP) of US$40 000 for the eight countries.ConclusionMT is efficient versus MM alone for patients with low ASPECTS in eight countries across Europe. Patients with a large ischemic core could be treated with MT because it is both clinically beneficial and economically sustainable.Disclosure of InterestNothing to disclose.
  • Publisher: London: BMJ Publishing Group LTD
  • Language: English
  • Identifier: ISSN: 1759-8478
    EISSN: 1759-8486
    DOI: 10.1136/jnis-2023-ESMINT.3
  • Source: ProQuest Central
Back to results list
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait